Germany · Delayed Price · Currency is EUR Defence Therapeutics Company Description
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases.
The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; the ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; and mRNA vaccination program.
The company also offers Dendritic Cell (DC) cancer vaccines using Accum; a protein‐based vaccine formulation against COVID and infectious diseases; and a cervical cancer vaccine.
The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020.
The company was incorporated in 2017 and is headquartered in Montreal, Canada.
| Country | Canada |
| Founded | 2017 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Sebastien Plouffe |
Contact Details
Address: 7171 Rue Frederick-Banting Montreal, British Columbia H4S1Z9 Canada | |
| Phone | 514 947 2272 |
| Website | defencetherapeutics.com |
Stock Details
| Ticker Symbol | DTC |
| Exchange | Frankfurt Stock Exchange |
| Share Class | Class A Shares |
| Fiscal Year | July - June |
| Reporting Currency | CAD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sebastien Plouffe | Chief Executive Officer |
| Arnab De | Chief Financial Officer |
| Mark Lambermon | Chief Operating Officer |